Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Fruquintinib 4mg d1-21, q4w TAS102 35mg/m2，bid，d1-5，d15-19，q4w

Fruquintinib, TAS102

Ting Deng, MD

Jiayu Zhang, MD

This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.

A prospective study of Fruquintinib combined with TAS-102 for the posterior line treatment of advanced colorectal cancer is ongoing (NCT05004831). Both Fuquinitinib and TAS-102 are oral drugs, which are convenient to use and avoid the burden of frequent hospitalization. Whether this combination has considerable efficacy in gastric cancer is not clear.

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Phase II Clinical Study of Fruquintinib Combined TAS102 for Second-line Treatment of Advanced Gastric Cancer

Time from the start of treatment to the progression of the disease

Time from the start of treatment to the occurrence of death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer	NCT06102785	Gastric Cancer	Fruquintinib, T...	18 Years -	Tianjin Medical University Cancer Institute and Hospital
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer	NCT06102785	Gastric Cancer	Fruquintinib, T...	18 Years -	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for fruquintinib, tas102